US 12,409,197 B2
Synergistic bacterial compositions and methods of production and use thereof
Matthew R. Henn, Somerville, MA (US); Kevin Daniel Litcofsky, Boston, MA (US); Anthony Mario D'Onofrio, Northborough, MA (US); Toshiro K. Ohsumi, Cambridge, MA (US); Mary-Jane Lombardo Mckenzie, Arlington, MA (US); Geoffrey Von Maltzahn, Boston, MA (US); David N. Cook, Brooklyn, NY (US); David Arthur Berry, Brookline, MA (US); Noubar B. Afeyan, Lexington, MA (US); and John Grant Aunins, Doylestown, PA (US)
Assigned to Seres Therapeutics, Inc., Cambridge, MA (US)
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
Filed on Jan. 26, 2024, as Appl. No. 18/424,354.
Application 18/424,354 is a division of application No. 17/588,122, filed on Jan. 28, 2022, granted, now 11,918,612.
Application 17/588,122 is a division of application No. 16/230,807, filed on Dec. 21, 2018, granted, now 11,266,699, issued on Mar. 8, 2022.
Application 16/230,807 is a division of application No. 15/039,007, granted, now 10,258,655, issued on Apr. 16, 2019, previously published as PCT/US2014/067491, filed on Nov. 25, 2014.
Claims priority of provisional application 61/908,702, filed on Nov. 25, 2013.
Claims priority of provisional application 61/908,698, filed on Nov. 25, 2013.
Claims priority of provisional application 62/004,187, filed on May 28, 2014.
Prior Publication US 2024/0325464 A1, Oct. 3, 2024
Int. Cl. A61K 39/02 (2006.01); A23L 33/135 (2016.01); A61K 35/74 (2015.01); A61K 35/742 (2015.01); A61K 35/744 (2015.01); A61K 45/06 (2006.01); C12N 1/20 (2006.01); A61K 35/00 (2006.01)
CPC A61K 35/742 (2013.01) [A23L 33/135 (2016.08); A61K 35/74 (2013.01); A61K 45/06 (2013.01); C12N 1/20 (2013.01); A61K 2035/11 (2013.01); A61K 2035/115 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A method of functionally populating the gastrointestinal tract of a human subject in need thereof, comprising administering to the subject a composition comprising: (a) a first species of an isolated bacterium capable of forming a spore, (b) a second species of isolated bacterium capable of forming a spore, and (c) a third species of isolated bacterium capable of forming a spore, and (d) a capsule;
wherein the capsule encapsulates the first species, the second species, and third species; wherein the first species, the second species, and the third species are not identical;
wherein the first species is Clostridium orbiscindens, the second species is Clostridium bolteae, and the third species is Lachnospiraceae bacterium 5_1_57FAA,
wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to a 16S rDNA the sequence set forth in SEQ ID NO: 609; and
wherein a combination of the first species, the second species, and the third species is capable of decreasing and/or inhibiting the growth and/or colonization of at least one type of pathogenic bacteria.